Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with O
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q4 2022 | OLEYL ALCOHOL | TOPICAL | CREAM, AUGMENTED | 2.00 %w/w | Deletion | ||
| Q4 2022 | OPACODE S-1-8106 BLACK | ORAL | TABLET, EXTENDED RELEASE | NA | Deletion | ||
| Q4 2022 | OPADRY YS-1-10533A | ORAL | TABLET | 8.16 mg | Deletion | ||
| Q4 2022 | OPADRY YS-1-10533A | ORAL | TABLET, EXTENDED RELEASE | 40.00 mg | 80mg | Deletion | |
| Q4 2022 | OLEYL ALCOHOL | TOPICAL | CREAM | 10.00 %w/w | MDE Replacement | ||
| Q4 2022 | OLEYL ALCOHOL | TOPICAL | CREAM | 20mg | MDE Replacement | ||
| Q3 2022 | OPADRY II 31F58914 WHITE | ORAL | TABLET | 23.00 mg | MDE Replacement | ||
| Q4 2022 | OPADRY II 31F58914 WHITE | ORAL | TABLET | 92mg | MDE Replacement | ||
| Q3 2022 | OPADRY II Y-19-7483 CLEAR | ORAL | CAPSULE, EXTENDED RELEASE | 5.74 mg | MDE Replacement | ||
| Q4 2022 | OPADRY II Y-19-7483 CLEAR | ORAL | CAPSULE, EXTENDED RELEASE | 17mg | MDE Replacement | ||
| Q3 2022 | OPADRY OY-52945 YELLOW | ORAL | TABLET, FILM COATED | 11.95 mg | MDE Replacement | ||
| Q4 2022 | OPADRY OY-52945 YELLOW | ORAL | TABLET, FILM COATED | 24mg | MDE Replacement | ||
| Q3 2022 | OPADRY OY-LS-37200 BUFF | ORAL | TABLET | 10.05 mg | MDE Replacement | ||
| Q4 2022 | OPADRY OY-LS-37200 BUFF | ORAL | TABLET | 10mg | MDE Replacement | ||
| Q3 2022 | OPADRY YS-3-7031 CLEAR | ORAL | TABLET | 17.37 mg | MDE Replacement | ||
| Q4 2022 | OPADRY YS-3-7031 CLEAR | ORAL | TABLET | 69mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: October 1, 2022
Database Last Updated: October 19, 2022